Using RWE to Make Cost Decisions: A New Report
A recent article, published in JMCP (the Journal of Managed Care and Specialty Pharmacy), considers how RWE (real world… Read more
HEOR Feature
Featured
Value in Health Regional Issues: Cost-Effectiveness of Novel Kidney Disease Biomarker Screening
IgA nephropathy (IgAN) is a leading cause of end-stage kidney disease across the world. A new paper in Value in Health Regional explores the… Read more
Looking Into the Future of Life Sciences Industry
The life sciences industry’s impressive response to the COVID-19 was made possible by unprecedented collaboration between the pharmaceutical, medical… Read more
Early-Stage Biopharma Financing in 2022
In an article from earlier this year, Richard Ramko of Life Science Leader laid out the current landscape of early-stage biopharma financing. The… Read more
The Latest Blogs from tHEORetically Speaking
- Boston Strategic Partners Supplier Spotlight
- Unlocking the Value of Real-World Data to Provide Real-World Care
- HealthLumen Supplier Spotlight
- Trends and challenges in the Value, Evidence, and Access landscape: an interview with David Sykes, Head of VEA, Fishawack Health
- Differentiate Your Product From the Competition: Give Healthcare Decision Makers the Information They Need
